Benefits and Complications Following First-Line Treatment with Atezolizumab plus Bevacizumab in a Patient with HCC: a Case Report

Benefits and Complications Following First-Line Treatment with Atezolizumab plus Bevacizumab in a Patient with HCC: a Case Report

Show other versions (1)

Until recently, sorafenib was the only systemic treatment available for patients with advanced hepatocellular carcinoma (HCC) since its approval in 2007. In the IMbrave150 trial, atezolizumab plus bevacizumab, as first-line therapy, demonstrated improvement in overall survival (OS) and progression-f...

Full description

Bibliographic Details
Main Authors: Maria Celeste Palmarocchi, Marco Cefali, Antonio Galante, Stefania Rizzo, Sara De Dosso
Format: Article
Language:English
Published: THE HEALTHBOOK COMPANY LTD. 2022-03-01
Series:healthbook TIMES. Oncology Hematology
Online Access:https://doi.org/10.36000//hbT.OH.2022.11.064

Similar Items

Similar Items